Fundraising FoxDimension Capital — 2025 Investments
5 investments dated 2025 · listed companies and verified rows first · show all
Fiveonefour builds tooling focused on agent experience (AX), helping developers ship software that AI agents can use effectively.
AI & Machine LearningDeveloper ToolsSaaSPortland, US
Timote Gelinas Delisle(Executive Officer, Director, Promoter)Chris Crane(Founder)inNicolas Joseph(Founder)in
Board seatNan Li· per SEC Form D
Co-investorsFlybridge Capital PartnersMaterialized View CapitalVermilion Cliffs Ventures6 Dimensions CapitalRidge VenturesStage 2 Capital
NewLimit develops epigenetic reprogramming medicines to extend healthspan and treat age-related diseases at the intersection of computer science and biotechnology.
AI & Machine LearningBiotechLongevitySouth San Francisco, US
Brian Armstrong(Founder)inBlake Byers(Founder)inJacob Kimmel(Founder)inMichael Polansky(Executive Officer)
Board seatZavain Dar· per SEC Form D
Co-investorsS32Valor Equity Partners8VCAbstract Venturesage1Beyond Capital+15 more
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.
BiotechMedical DevicesCambridge, US
Gary D Glick(Executive Officer, Director)inGary D. Glick(Founder)Gary D. Glick, Ph.D.(Founder, President & CEO)
BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)
Board seatNan Li· per SEC Form D
Co-investorsActivant CapitalAscenta CapitalBalderton CapitalCatalio Capital Management, LPForesite CapitalGlobal BioAccess Fund+9 more
Stately Bio develops stem cell-derived regenerative and cell therapies using a machine learning platform that measures cell identity, behavior, and maturation directly from live-cell, label-free imaging.
AI & Machine LearningBiotechMedical Devices
Frank Li(Founder & CEO)Christian Elabd, PhD(Head of Biology)
Co-investorsAIX VenturesFoothill VenturesMitsui Global InvestmentAxial VCBoxOne VenturesCaffeinated Capital+1 more
Tamarind provides a computational platform for protein and molecular engineering, offering AI and physics-based tools to design antibodies, peptides, enzymes, and small molecules.
AI & Machine LearningBiotechDeep TechEnterprise SoftwareSaaSSan Francisco, US
Deniz Kavi(CEO)inSherry Liu(Founder)inBrooke Lacina(Recruiter)Recruiting Tamarind Bio(Recruiter)Abraham Penuelas(Technical Recruiter)
Co-investorsEight CapitalLynett Capital PartnersTranspose Platform ManagementTreeo VCY Combinator468 Capital+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.